Antifungal Drugs Market: By Drug Class (Azoles, Polyenes, Echinocandins, Allylamines, Others), By Route of Administration (Oral, Parenteral, Topical), By Therapeutic Indications (Aspergillosis, Candidiasis, Dermatophytosis, Others), By Distribution Channel (Retail Pharmacies, Hospital pharmacies, Drug stores, Online pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Antifungal Drugs Market size was valued at USD 15,623.8 million in 2022 and is expected to grow at a CAGR of 3.9% from 2023 to 2029. The global market provides a detailed overview that can be segmented by drug type, route of administration, Therapeutic indication, and by distribution channel. By drug type, the Antifungal Drugs market growth has been segmented into Azoles, Polyenes, Echinocandins, Allylamines, and Others. The Azoles segment is likely to be the largest and fastest-growing segment in terms of drug type. Azoles are used to treat candidemia, blastomycosis, ocular fungal infections, and systemic candidiasis. It helps in fungistatic activities by hindering fungal enzymes. Azoles are also utilized in the treatment of systemic fungal infections, divided into imidazoles and triazoles. They provide an extensive spectrum of activity along with improved safety levels. Triazoles have less severe effects, fewer serious drug interactions, and enhanced distribution and absorption properties. The above-mentioned advantages of the use of azoles are attributed to the antifungal drug market share. Based on the Route of administration, the Antifungal Drugs market is segmented into Oral, Parenteral, and Topical. Among these, the Topical route of administration segment is expected to have a significantly growing market during the forecast period. Based on the Therapeutic indication, the Antifungal Drugs market is segmented into Aspergillosis, Candidiasis, Dermatophytosis, and Others. The Candidiasis segment is expected to have a significant share in 2021. Candidiasis is the most frequently happening systemic fungal infection. It is a yeast infection by the genus Candida. Its process to cure has changed over time. Some of the variations comprise suitable usage of broad-spectrum azoles and echinocandins for the treatment of candidemia, invasive candidiasis, and mucosal candidiasis. Based on the distribution channel, the Antifungal Drugs market is segmented into Retail pharmacies, Hospital pharmacies, Drug stores, and Online pharmacies.

Antifungal Drugs Market Key Development:

  • In June 2021, Mankind Pharma launched Posaconazole Gastro which was a tablet for drug resistance.
  • In June 2021, Cadila Pharmaceuticals launched Posaconazole which can be used against an extensive range of fungal disorders.

Global Anti Fungal Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.9%

Largest Market

North America

Fastest Growing Market

Europe
Antifungal Drugs Market Dynamics

The growing incidences of nosocomial and fungal infections are anticipated to propel the market growth over the forecast years. Moreover, the growing healthcare expenditure, which helps in refining its infrastructure, is burgeoning the market growth over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Anti Fungal Drugs Market Segmentation

By Drug Class
  • Azoles
  • Polyenes
  • Echinocandins
  • Allylamines
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Topical
By Therapeutic Indication
  • Aspergillosis
  • Candidiasis
  • Dermatophytosis
  • Others
By Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies
  • Drug stores
  • Online pharmacies

Frequently Asked Questions

The anti-fungal drugs market size was valued at USD 15,623.8 million in 2022

The anti-fungal drugs market key players are: Pfizer, Inc. (U.S.) Novartis AG (Switzerland) Sanofi (France) Merck & Co., Inc. (U.S.) Enzon Pharmaceuticals, Inc. (U.S.) Bayer AG (Germany) Astellas Pharma, Inc. (Japan) GlaxoSmithKline plc. (U.K.) Mylan N.V. (U.S.) Tecan Group (Switzerland) AureoGen Biosciences Inc. (U.S.)

The anti fungal drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Anti-fungal Drugs Market Introduction
2.1. Global Anti-fungal Drugs Market – Taxonomy
2.2. Global Anti-fungal Drugs Market – Definitions
2.2.1. Drug Class
2.2.2. Route of Administration
2.2.3. Therapeutic Indications
2.2.4. Distribution Channel
3. Global Anti-fungal Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Anti-fungal Drugs Market Dynamic Factors - Impact Analysis
3.6. Global Anti-fungal Drugs Market – Competition Landscape
3.7. Epidemiology
4. Global Anti-fungal Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Anti-fungal Drugs Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Azoles
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Polyenes
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Echinocandins
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Allylamines
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Anti-fungal Drugs Market Forecast, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Oral
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Topical
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Anti-fungal Drugs Market Forecast, By Therapeutic Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. Aspergillosis
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Candidiasis
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Dermatophytosis
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Anti-fungal Drugs Market Forecast (2018 - 2022 and 2023 - 2029)
8.1. Retail Pharmacies
8.1.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Hospital Pharmacies
8.2.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Drug Stores
8.3.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Online Pharmacies
8.4.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
9. Global Anti-fungal Drugs Market Forecast by Region (2018 - 2022 and 2023 - 2029)
9.1. North America
9.1.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis (2018 - 2022 and 2023 - 2029) (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
10. Global Anti-fungal Drugs Market - Opportunity Analysis Index
10.1. By Drug Class, Route of Administration, Therapeutic Indications, Distribution Channel, and Region (2023 - 2029)
11. North America Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029)
11.1. Drug Class Analysis
11.1.1. Azoles
11.1.2. Polyenes
11.1.3. Echinocandins
11.1.4. Allylamines
11.1.5. Others
11.2. Route of Administration Analysis
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Topical
11.3. Therapeutic Indications Analysis
11.3.1. Aspergillosis
11.3.2. Candidiasis
11.3.3. Dermatophytosis
11.3.4. Others
11.4. Distribution Channel Analysis
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Drug Stores
11.4.4. Online Pharmacies
11.5. Country Analysis
11.5.1. U.S.
11.5.2. Canada
11.6. North America Anti-fungal Drugs Market - Opportunity Analysis Index
Continue this format for sections 12, 13, and 14 for Europe, Asia-Pacific, and Latin America, respectively.
12. Europe Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029)
12.1. Drug Class Analysis
12.1.1. Azoles
12.1.2. Polyenes
12.1.3. Echinocandins
12.1.4. Allylamines
12.1.5. Others
12.2. Route of Administration Analysis
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Topical
12.3. Therapeutic Indications Analysis
12.3.1. Aspergillosis
12.3.2. Candidiasis
12.3.3. Dermatophytosis
12.3.4. Others
12.4. Distribution Channel Analysis
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Drug Stores
12.4.4. Online Pharmacies
12.5. Country Analysis
12.5.1. Germany
12.5.2. UK
12.5.3. France
12.5.4. Spain
12.5.5. Italy
12.5.6. Russia
12.5.7. Poland
12.5.8. Rest of Europe
12.6. Europe Anti-fungal Drugs Market - Opportunity Analysis Index
13. Asia-Pacific Anti-fungal Drugs Market Analysis (2018 - 2022 and 2023 - 2029)
13.1. Drug Class Analysis
13.1.1. Azoles
13.1.2. Polyenes
13.1.3. Echinocandins
13.1.4. Allylamines
13.1.5. Others
13.2. Route of Administration Analysis
13.2.1. Oral
13.2.2. Parenteral
13.2.3. Topical
13.3. Therapeutic Indications Analysis
13.3.1. Aspergillosis
13.3.2. Candidiasis
13.3.3. Dermatophytosis
13.3.4. Others
13.4. Distribution Channel Analysis
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Drug Stores
13.4.4. Online Pharmacies
13.5. Country Analysis
13.5.1. Japan
13.5.2. China
13.5.3. India
13.5.4. ASEAN
13.5.5. Australia & New Zealand
13.5.6. Rest of Asia-Pacific
13.6. Asia-Pacific Anti-fungal Drugs Market - Opportunity Analysis Index
14. Latin America Anti-fungal Drugs Market Analysis (2012 - 2018 - 2022 and 2023 - 2029)
14.1. Drug Class Analysis
14.1.1. Azoles
14.1.2. Polyenes
14.1.3. Echinocandins
14.1.4. Allylamines
14.1.5. Others
14.2. Route of Administration Analysis
14.2.1. Oral
14.2.2. Parenteral
14.2.3. Topical
14.3. Therapeutic Indications Analysis
14.3.1. Aspergillosis
14.3.2. Candidiasis
14.3.3. Dermatophytosis
14.3.4. Others
14.4. Distribution Channel Analysis
14.4.1. Retail Pharmacies
14.4.2. Hospital Pharmacies
14.4.3. Drug Stores
14.4.4. Online Pharmacies
14.5. Country Analysis
14.5.1. Brazil
14.5.2. Mexico
14.5.3. Argentina
14.5.4. Venezuela
14.5.5. Rest of Latin America
14.6. Latin America Anti-Fungal Drugs Market - Opportunity Analysis Index
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Pfizer, Inc. (U.S.)
 15.2.2. Novartis AG (Switzerland)
 15.2.3. Sanofi (France)
15.2.4. Merck & Co., Inc. (U.S.)
 15.2.5. Enzon Pharmaceuticals, Inc. (U.S.)
15.2.6. Bayer AG (Germany)
 15.2.7. Astellas Pharma, Inc. (Japan)
15.2.8. GlaxoSmithKline plc. (U.K.)
 15.2.9. Mylan N.V. (U.S.), Tecan Group (Switzerland)
 15.2.10. AureoGen Biosciences Inc. (U.S.)
16. Research Methodology
17. Key Assumptions and Acronyms
  • Pfizer, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Merck & Co., Inc. (U.S.)
  • Enzon Pharmaceuticals, Inc. (U.S.)
  • Bayer AG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • GlaxoSmithKline plc. (U.K.)
  • Mylan N.V. (U.S.)
  • Tecan Group (Switzerland)
  • AureoGen Biosciences Inc. (U.S.)

Adjacent Markets